Biometric & Lab ScreeningsDebunking the myths to unlock the power of Total Population Health Management

2Hooper Holmes Confidential

Hooper Holmes Health & Wellness

New division of 109 year old health information company— 9,000+ examiners

— CLIA/CAP/NGSP certified laboratory

— FDA approved medical device manufacturer

— 50,000 sq foot warehouse and shipping facility

Provide services exclusively to health & care management companies— Do not market to, or contract with, employers

— Private labeled screening solution (the “Intel Inside”)

Screen groups and individuals in a variety of ways — Screen both individuals and groups of all sizes

— Venipucture, Cholestech, self-collection kits

2008 accomplishments— 200,000 health & wellness screenings completed

— 4,000+ screening events in over 1,700 cities in all fifty states, DC & PR

— 99.6% participant satisfaction

3Hooper Holmes Confidential

Agenda

I. Role of Screenings in Total Population Health Page 4

II. Debunking Common Screening Myths Page 8

III. Enabling Total Population Health Management Page 14

4Hooper Holmes Confidential

Care Management is moving to the left

The move to total population health management

Well At Risk IllChronically

IllAcutely

Ill

Managing CostsReversing the Trend

20%of population

80%of population

150+ Million Covered Lives

5Hooper Holmes Confidential

Biometric & lab data is a key enabler

Biometric & Lab Data

Claims Data

Well At Risk IllChronically

IllAcutely

Ill

Today’s CostTomorrow’s Cost

6Hooper Holmes Confidential

The importance of lab and biometric data

Claims data is too late— Participant is already ill

— Good for cost management, not cost avoidance

— Can’t help reverse the trend

HRA data alone is not enough— 74% of respondents don’t know their biometric or lab data

— Only reinforces what the participant knows

Lab and biometric data fills in the gaps— Data on those that you have no data on

— Objective data that uncovers unknown risks

— Provides a baseline and the data necessary to address the trend

7Hooper Holmes Confidential

Agenda

I. Role of Screenings in Total Population Health Page 4

II. Debunking Common Screening Myths Page 8

III. Unlocking Total Population Health Management Page 14

8Hooper Holmes Confidential

Origins of the myth

Consumers don’t know what’s possible or available

Historical disconnect between health & care mgmt.

Historical lack of programs to act upon the data

Screenings viewed only as an employee benefit

Screenings viewed as a “product”

Debunking the myth

Stand alone health fairs can’t pass the ROI test

The real value of screenings is the data collected

Ongoing engagement outperforms “teachable moment”

Screenings are the front-end to other products

SCREENING MYTH #1: Health fairs work

9Hooper Holmes Confidential

Screenings aren’t an “event” but the start of a “process”

BiometricScreenings

UncoverRisks Stratify

Pop

EstablishBaseline

TargetPrograms

EngageParticip.Motivate

Change

MeasureROI

Debunking the myth

10Hooper Holmes Confidential

Origins of the myth

DMAA study shows that providers see better incentives as having the greatest impact on program success

Poor engagement strategies have been combated with higher incentives to increase participation

Incentives viewed as a stand-alone program component

Debunking the myth

Employers see better identification of at-risk participants as having the greatest impact on program success

All parties agree that engagement is key to success

Incentives that are linked to coverage and program design can drive participation and engagement

SCREENING MYTH #2:

incentive = participation =

engagement

11Hooper Holmes Confidential

Debunking the myth

HRA & screening = incentive

HRA & screening & doing something about it = incentive

Incentive = cash or cash equivalent

Incentive = plan feature generating cost shifting

Warning: Incentive and program cannot become adversarial to participants!

What to incent

How to incent

12Hooper Holmes Confidential

Operational Myths

A. Fingerstick is cheaper than venipuncture with lab testing

B. Screening “stations” are more efficient

C. You can’t efficiently reach remote individuals

Debunking the myths

A. A Cholestech cassette & full lab panel both cost $10

B. Stations are championed by providers who don’t have enough phlebotomists or Cholestech machines

C. Individuals can be screened in home or office or with self-collection kits – without breaking the bank

SCREENING MYTH #3:Operational misunderstandings

13Hooper Holmes Confidential

Agenda

I. Role of Screenings in Total Population Health Page 4

II. Debunking Common Screening Myths Page 8

III. Unlocking Total Population Health Management Page 14

14Hooper Holmes Confidential

Redefining the role of biometric screenings

Screenings are not:— A product

— An event

— Simply an employee benefit

Screenings are:— A “feeder” for other products

— The beginning of an engagement process

— A powerful source of data

15Hooper Holmes Confidential

Integrating health & care management

Data integration— Lab & biometric data with claims & pharmacy data

— Use screening data to establish a baseline to demonstrate future ROI of health management

Product integration— Screenings “feed” disease management

— Screenings as the front-end to intervention programs

Incentive integration— Incent action - not just participation

— Integrated incentive to shift costs

16Hooper Holmes Confidential

ScreeningData

ParticipantEngagement

TargetedPrograms

StratifiedPopulation

=

Role of screenings in total population health

Claims & RxData

+

Incentive ROI(2nd time around)